Chester County News and Community Website
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced plans to showcase updated clinical data on its investigational CD19-CAR T cell therapy, resecabtagene autoleucel (rese-cel), during two prominent scientific conferences this …
Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced its participation in Guggenheim’s SMID Cap Biotech Conference, scheduled for Wednesday, February 5, 2025, at 10:30 a.m. ET in New …
Cabaletta Bio to Present at Guggenheim’s SMID Cap Biotech Conference Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has revealed significant progress in its pipeline and operations, underscoring its focus on advancing rese-cel, a cell therapy candidate for autoimmune diseases. …
Cabaletta Bio Advances Autoimmune Therapy, Sets Strategic Goals for 2025 Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) recently presented encouraging clinical data for its investigational therapy, CABA-201, at the American College of Rheumatology (ACR) Convergence 2024 in Washington, D.C. …
Cabaletta Bio Unveils Promising Data on CABA-201 at ACR Convergence 2024 Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has released its financial results for the third quarter of 2024, alongside updates on its clinical trial programs. A key highlight includes …
Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Monday, November 11, 2024, at 10:00 a.m. ET in …
Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim’s Healthcare Innovation Conference! Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) is set to unveil new clinical data on its investigational therapy, CABA-201, at the American College of Rheumatology (ACR) Convergence 2024. The …
Cabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024 Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced its participation in a series of influential investor conferences this September.
Cabaletta Bio, Inc. Set to Engage at Key Investor Conferences Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced its financial results for the second quarter ended June 30, 2024, along with key business updates.
Cabaletta Bio Reports Q2 2024 Financial Results and Provides Business Update Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced that Steven Nichtberger, M.D., its Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Virtual Cell Therapy …
Cabaletta Bio CEO to Speak at Stifel 2024 Virtual Cell Therapy Forum Read More